Clinical Trials
1,017 trialsNCT04108195 2026-06-05
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04133636 2026-06-05
CARTITUDE-2
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT04634552 2026-06-05
MonumenTAL-1
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT04722146 2026-06-05
MajesTEC-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT04923893 2026-06-05
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05050097 2026-06-05
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05201781 2026-06-05
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Janssen Research & Development, LLC
Phase 4 Recruiting
NCT05363800 2026-06-05
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
NCT05438043 2026-06-05
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05552222 2026-06-05
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05650632 2026-06-05
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1 Recruiting
NCT05652335 2026-06-05
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06057402 2026-06-05
MagnetisMM15
Pfizer
Phase 4 Recruiting
NCT06152575 2026-06-05
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT06158841 2026-06-05
CERVINO
AbbVie
Phase 3 Recruiting
NCT06208150 2026-06-05
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06500884 2026-06-05
Talisman
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT06550895 2026-06-05
MonumenTAL-8
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT06577025 2026-06-05
aMMbition
Janssen Research & Development, LLC
Phase 2 Active not recruiting
NCT06604715 2026-06-05
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT07030517 2026-06-05
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Johnson & Johnson Private Limited
Phase 4 Recruiting
NCT07149857 2026-06-05
CARTITUDE-10
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07258511 2026-06-05
TRIlogy-4
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07266441 2026-06-05
TRIlogy-3
Janssen Research & Development, LLC
Phase 2 Recruiting
NCT07518186 2026-06-05
TRIlogy-5
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06140524 2026-06-04
LINKER-MGUS1
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT06615479 2026-06-04
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT07255898 2026-06-04
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07490613 2026-06-04
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05519085 2026-06-03
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT05583617 2026-06-03
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05927571 2026-06-03
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Genentech, Inc.
Phase 1 Recruiting
NCT07623798 2026-06-03
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Not yet recruiting
NCT03652064 2026-06-02
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Completed
NCT05184088 2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3 Completed
NCT06106945 2026-06-02
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AstraZeneca
Phase 1/2 Recruiting
NCT06953960 2026-06-02
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1/2 Recruiting
NCT07095452 2026-06-02
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT07227311 2026-06-02
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 2 Recruiting
NCT07614360 2026-05-29
DREAMM-16
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT06297226 2026-05-28
QUINTESSENTIAL
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2 Recruiting
NCT06988488 2026-05-28
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Phase 1/2 Recruiting
NCT07195617 2026-05-28
r/r MM
Guangzhou Bio-gene Technology Co., Ltd
Phase NA Withdrawn
NCT07611149 2026-05-28
Study to Evaluate the Safety of UF-KURE-BCMA CAR T-Cells in Advanced Myeloma
Kure Cells, INC
Phase 1 Not yet recruiting
NCT05839626 2026-05-27
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1 Terminated
NCT06566547 2026-05-27
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 2 Active not recruiting
NCT07073547 2026-05-27
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
AstraZeneca
Phase 1 Recruiting
NCT07555938 2026-05-27
CEVOLUTION
Hoffmann-La Roche
Phase 3 Recruiting
NCT07609706 2026-05-27
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT07609940 2026-05-27
POPLIN
Regeneron Pharmaceuticals
Phase 4 Not yet recruiting